Skip to main content
Grafa
Health
Annexon reports pipeline updates and $55.3 million loss
Image for illustrative purposes only. Not a real photo.

Annexon reports pipeline updates and $55.3 million loss

Share
  • Annexon (NASDAQ:ANNX) reported second-quarter 2026 results, including a net loss of $55.3 million and updates on its clinical programs.
  • The company held $209.2 million in cash, cash equivalents and short-term investments at June 30, 2026, and secured a credit facility of up to $200 million.
  • Annexon expects a U.S. BLA submission for tanruprubart in Q4 2026 and continued progress in its Phase 3 ARCHER II study.

Annexon (NASDAQ:ANNX) reported second-quarter 2026 financial results and clinical pipeline updates, including a net loss of $55.3 million, or $0.28 per share, for the quarter ended June 30, 2026.

The company’s update followed progress across its programs, with tanruprubart in Guillain-Barré syndrome (GBS) showing early improvements in strength and disability measures among the first 10 FORWARD study patients.

Research and development expenses increased to $46.6 million, general and administrative expenses rose to $10.6 million, and Annexon secured a credit facility of up to $200 million with an initial $50 million drawn.

Annexon said a U.S. Biologics License Application submission for tanruprubart is expected in Q4 2026, while the European Union marketing application remains under review.

The company said its Phase 3 ARCHER II trial for geographic atrophy remains on track, with dual primary endpoints at Months 15 and 24 and an open-label extension now launched.

Annexon also reported $209.2 million in cash, cash equivalents and short-term investments as of June 30, 2026, and said it expects its financial runway to extend into 2028.

Frequently asked questions